Orasis Pharmaceuticals
PrivateLast Round
Series D
Oct 8, 2024
Total Funding Raised
$126M
Company Overview
Orasis Pharmaceuticals operates in Healthcare & Life Sciences and is based in Ponte Vedra Beach, Florida. Its latest recorded funding round was a Series D round in October 2024.
Orasis Pharmaceuticals is a pharmaceutical company that develops and markets ophthalmic solutions, including its FDA-approved prescription eye drop Qlosi for the treatment of presbyopia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Orasis Pharmaceuticals Comparables
Compare Orasis Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LENZ Therapeutics | 87% | |
| AbbVie | 83% | |
| Nevakar Inc. | 82% |
For institutional investors. Book with your work email.
Orasis Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Oct 8, 2024 | ||||
| Debt | Oct 8, 2024 | ||||
| Series C | Sep 10, 2020 | ||||
| Series B | Jun 5, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Orasis Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LifeSci Venture Partners | Series C, Series B |
| Arboretum Ventures | Series D |
| Maverick Ventures | Series C, Series D |
| Maverick Ventures Israel | Series C |
| SBI JI | Series D, Series B, Series C |
| Catalio Capital Management | Debt, Series D |
| Maverick Ventures | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 8, 2024
$68M round led by Johnson & Johnson Innovation and Arboretum Ventures.
- Sep 10, 2020
$30M round led by Bluestem Capital, SBI JI, and Visionary Ventures.
For institutional investors. Book with your work email.
Orasis Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Orasis Pharmaceuticals's valuation, stock price, and market status.
Is Orasis Pharmaceuticals a public or private company?
Orasis Pharmaceuticals is a private company.
What is the current stock price of Orasis Pharmaceuticals?
Orasis Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Orasis Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Orasis Pharmaceuticals worth (valuation)?
Valuation information for Orasis Pharmaceuticals is not publicly available.
Can I buy Orasis Pharmaceuticals stock?
Orasis Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Orasis Pharmaceuticals's last funding round?
Orasis Pharmaceuticals's most recent funding round was Series D on October 8, 2024.
Who are the main investors in Orasis Pharmaceuticals?
Key investors in Orasis Pharmaceuticals include Arboretum Ventures, SBI JI, Johnson & Johnson Innovation – JJDC, Visionary Ventures, Johnson & Johnson Innovation - JJDC, Inc..
Will Orasis Pharmaceuticals IPO soon?
No public IPO plans have been announced for Orasis Pharmaceuticals.
How can I track Orasis Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Orasis Pharmaceuticals's shares on secondary markets.